Good MorningEquity markets started the holiday-shortened week on solid footing, advancing incrementally to hover near record highs. The move was partly supported by President-elect Trump's pick of Scott Bessent for Treasury Secretary. The market favors the pick because his economic views will temper Donald Trump's more aggressive stance and reduce the risk of inflation accelerating.
The hurdle for markets this week is Wednesday. The economic calendar contains market-moving reports, including the Fed minutes and PCE price index. The PCE price index is expected to reveal inflation accelerating at the headline and core levels, contradicting the trend that led the FOMC to cut rates in September. This will be the second month inflation has increased since the Fed first cut rates, and it will likely keep them from cutting again in December, news that may keep the S&P 500 from hitting another new high this year. Featured: Trump won. Buy this coin now. (Weiss Ratings) 
|
Markets | | |
Super Micro Computer (NASDAQ: SMCI) helped mitigate market fear by announcing the appointment of its new auditor and putting a bottom in its stock price decline. BDO USA is part of a global franchise among the world’s top five accounting firms, so its approval will carry weight. The only q... Read the Full Story |
|
From Our PartnersNow is the time to consider a time-tested asset favored by conservative investors for navigating market volatility and building long-term security. Whether the results lean toward continuity or change, this asset remains a stable cornerstone for safeguarding wealth and driving growth.
By following the link, you're choosing to opt in to receive insightful updates from Wealth Creation Investing + 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details. | | | | [Download the Free Guide Now] to explore the potential of this strategy and discover what may be missing from your financial plan. |
|
Stocks | | | U.S. stocks rose Monday, with those benefiting the most from lower interest rates and a stronger economy leading the way.The S&P 500 climbed 0.3% to pull closer to its all-time high set two weeks ago. The Dow Jones Industrial Average added 440 points, or 1%, to its own record set on Friday, whil... Read the Full Story |
|
Markets | | |
With the Trump administration taking over in January 2025, there has been much speculation about forthcoming changes, trends, and themes. With Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk firmly embedded in Trump’s inner circle, there’s been speculation that self-driving or autonomous cars ... Read the Full Story |
|
|
Markets | | | Investor Warren Buffett renewed his Thanksgiving tradition of giving by handing out more than $1.1 billion of Berkshire Hathaway stock to four of his family's foundations Monday, and he offered new details about who will be handing out the rest of his fortune after his death Read the Full Story |
|
Markets | | |
Following the 2024 U.S. election, there has been a great deal of speculation about how a second Trump administration will set policies that have an impact on the economy. Some have taken a strongly optimistic view of what's to come—a recent Goldman Sachs report suggested that the likelihood ... Read the Full Story |
|
From Our PartnersWhile other cell phone carriers are always looking for ways to squeeze every last penny out of their customers, my company pays users for the 40 hours a week they are using smartphone apps, listening to music, and watching videos online with their phones.
And you can join us for just $0.26 per share. Plus, when you invest now, you can get up to 100% bonus shares! | | | | Let’s change the future of mobile together. |
|
Markets | | | Global shares retreated on Tuesday as worries spread over President-elect Donald Trump's comment that he plans to impose sweeping new tariffs on Mexico, Canada and China as soon as he takes office.France's CAC 40 declined 0.9% in early trading to 7,195.07, while Germany's DAX slipped 0.6% to 19,288.... Read the Full Story |
|
Markets | | |
Abacus Life, Inc. (NASDAQ: ABL) is a global alternative asset manager specializing in a unique niche within the financial markets. The company acquires and manages life insurance policies.
The company's core mission is to generate financial returns for investors and educate consumers on the of... Read the Full Story |
|
Markets | | | Bath & Body Works fiscal third-quarter performance topped analysts' estimates thanks to strong sales, and the retailer boosted its full-year outlook.The owner of Victoria’s Secret, Bath & Body Works and other chain stores earned $106 million, or 49 cents per share, for the period. A year ear... Read the Full Story |
|
Stocks | | | Donald Trump has big plans for the economy — and a big debt problem that will be a hurdle to delivering on them.Trump has bold ideas on tax cuts, tariffs and other programs, but high interest rates and the price of repaying the federal government’s existing debt could limit what he’s able to do.Not ... Read the Full Story |
|
Markets | | |
Investing in companies in their first year of being publicly traded can be an exciting and perilous proposition. It may take time for enough information to come out about a new stock before the market can gather a strong sense of its actual value, leading to volatility. Shares can see large uptick... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. | Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Thursday, November 21, 2024 at 10:29 PM.
Pros-
The stock is currently priced at approximately $83.78, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
-
Recent analyst upgrades have increased price targets for Gilead Sciences, Inc., with JPMorgan Chase & Co. raising their target to $105.00, indicating strong potential for price appreciation.
-
Gilead Sciences, Inc. has a diverse portfolio of medicines addressing unmet medical needs, which can lead to sustained revenue growth and market presence.
-
Insider transactions show confidence in the company, with recent sales being relatively small compared to overall ownership, suggesting that insiders still hold significant stakes.
-
The company has a strong research and development pipeline, which is crucial for long-term growth in the biopharmaceutical industry.
Cons-
The payout ratio is extremely high at 3,422.22%, indicating that the company is paying out significantly more in dividends than it earns, which may not be sustainable.
-
Insider sales have occurred recently, which could signal a lack of confidence in the stock's short-term performance.
-
Despite positive analyst ratings, the stock has a mixed outlook with many analysts maintaining a "hold" rating, suggesting caution among investors.
-
Recent insider ownership is only 0.16%, which may indicate a lack of alignment between management and shareholder interests.
-
Market volatility and regulatory challenges in the biopharmaceutical sector can impact Gilead Sciences, Inc.'s stock performance unpredictably.
| | View Today's Stock Pick |
|
